Ascendis Pharma A/S reports results for the quarter ended in December - Earnings Summary

Ascendis Pharma A/S

07/02/2024 22:02

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €1.54​​ per share for the quarter ended in December, higher
than the same quarter last year, when the company reported EPS
of €-3.70.  The mean expectation of eleven analysts for the
quarter was for a loss of €2.03 per share. Wall Street expected
results to range from €-4.06 to -36 cents per share.
    * Revenue rose 360.2% to €137.70 million from a year ago;
analysts
expected €63.12 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€1.54​.
    * The company reported a quarterly loss of €86.88 million.
    * Ascendis Pharma A/S shares had risen by 11.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 15.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $170.26 

This summary was machine generated from LSEG data February 7 at
10:02 p.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -2.03          -1.54          Beat
 Sep. 30 2023      -2.38          -2.88          Missed
 Jun. 30 2023      -2.59          -2.16          Beat
 Mar. 31 2023      -2.66          -1.98          Beat